EPIX Contrast Agents Subject of Three Presentations At AHA.Business Editors/Health/Medical Writers CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2003 EPIX EPIX Emergency Preparedness Information Exchange EPIX Enhanced Performance unIX EPIX European Property Stock Index Medical, Inc. (Nasdaq: EPIX), a developer of specialty pharmaceuticals for magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ), today announced that three presentations concerning EPIX research and clinical programs for contrast-enhanced MRI will be delivered at the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. 76th Scientific Sessions in Orlando, FL. The EPIX thrombus thrombus /throm·bus/ (throm´bus) pl. throm´bi a stationary blood clot along the wall of a blood vessel, frequently causing vascular obstruction. imaging program is the subject of two of the presentations. On Monday, November 10th a poster by Marc Sirol, Ph.D. (New York, NY) entitled "Arterial Thrombus Detection and Temporal Evolution Evaluation Using In Vivo Molecular Magnetic Resonance Imaging (MRI)," will be available from 8:30 AM - 5:00 PM. At 4:15 PM on Monday, a talk entitled "In-Vivo Coronary Artery Imaging of In-Stent Thrombosis Using a Fibrin-Binding Molecular Contrast Agent and a Novel MR Translucent Stent," will be presented by Arno Buecker (Aachen, Germany). EP-2104R, EPIX' molecularly targeted thrombus imaging agent, incorporates proprietary receptor-induced magnetic enhancement (RIME) technology and is designed to bind with high specificity to the fibrin found in all blood clots. The Company plans to commence human trials of EP-2104R in 2004. On Monday, November 10, from 3:00-4:30, "Results of MS-325-13: a Phase III Magnetic Resonance Angiography Magnetic resonance angiography A noninvasive diagnostic technique that uses radio waves to map the internal anatomy of the blood vessels. Mentioned in: Cerebral Aneurysm magnetic resonance angiography (MRA MRA Medical Record Administrator. MRA Magnetic resonance angiography, see MR angiography ) Trial with MS-325, a Blood Pool Contrast Agent, for the Detection of Aortoiliac Occlusive Disease aortoiliac occlusive disease n. Obstruction of the abdominal aorta and its main branches by atherosclerosis. Also called Leriche's syndrome. (AIOD)" will be presented in a poster by Emile Mohler, M.D. (Philadelphia, PA.). Dr. Mohler's presentation discusses results of the second Phase III trial in the aortoiliac arteries released in March, 2003. Conference Call As previously announced, EPIX will also host a conference call and live webcast of its conference call discussing new clinical data concerning MS-325 renal safety study data at 4:30 pm EST EST electroshock therapy. EST abbr. electroshock therapy on Monday, November 10, 2003. Michael D. Webb, Chief Executive Officer, will host the call. The dial-in number for the EPIX Medical conference call is 888-464-7607, with reservation code 3835540. A recording of this call may be accessed until Friday, November 21, by calling 800-642-1687, using reservation code 3835540. The press release and the conference call webcast can also be accessed by visiting the EPIX website at www.epixmed.com. Please connect to the EPIX website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the live webcast. Two hours after the live webcast and through Friday, November 28, 2003, an archived version of the call will be available on the EPIX website by clicking "Investor Relations." EPIX, based in Cambridge, MA, is a specialty pharmaceutical company and a leading developer of targeted MRI contrast agents for the diagnosis and clinical management of disease. The Company believes that MS-325, its lead product under development, has the potential to be an alternative to invasive X-ray angiography as a diagnostic tool for vascular imaging. On the strength of four successful MS-325 Phase III clinical trials, the Company plans to submit a New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in 2003. Schering AG, the market leader in MRI contrast agent sales, is the sales and marketing partner for MS-325. EPIX is also collaborating with Schering AG in the development of its second drug candidate, EP-2104R, for imaging blood clots using MRI, and in a research partnership to discover novel compounds for MRI. To receive the latest EPIX news and other corporate developments, please visit the EPIX website at www.epixmed.com. This news release contains forward-looking statements based on current expectations of the Company's management. Such statements are subject to risks and uncertainties which could cause actual results to differ from those projected, including risks and uncertainties related to the conduct of, and results obtained from, our clinical trials, our dependence on corporate collaborations, our ability to develop multiple applications for our products and technologies, market acceptance of our products, reimbursement policies of third-party payors with respect to our products, competition and technological change. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion